Literature DB >> 18786178

Involvement of nuclear factor-kappa B in bcl-xL-induced interleukin 8 expression in glioblastoma.

Chiara Gabellini1, Laura Castellini, Daniela Trisciuoglio, Michael Kracht, Gabriella Zupi, Donatella Del Bufalo.   

Abstract

We recently reported that bcl-xL regulates interleukin 8 (CXCL8) protein expression and promoter activity in glioblastoma cells. In this paper we demonstrate that CXCL8 induction by bcl-xL is mediated through a nuclear factor-kappa B (NF-kB)-dependent mechanism. Mutational studies on the CXCL8 promoter showed that NF-kB binding site was required for bcl-xL-induced promoter activity and an enhanced nuclear expression of NF-kB subunits p65 and p50 was observed after bcl-xL over-expression. Electrophoretic mobility shift assay showed an increased DNA-binding activity of NF-kB in bcl-xL over-expressing cells and the use of specific antibodies confirmed the involvement of p65 and p50 in NF-kB activity on CXCL8 promoter sequence. NF-kB activity regulation by bcl-xL involved IkBalpha and IKK complex signaling pathway. In fact, bcl-xL over-expression induced a decrease of cytoplasmic expression of the IkBalpha protein, paralleled by an increase in the phosphorylation of the same IkBalpha and IKKalpha/beta. Moreover, the down-regulation of the ectopic or endogenous bcl-xL expression through RNA interference confirmed the ability of bcl-xL to modulate NF-kB pathway, and the transient expression of a degradation-resistant form of the cytoplasmic NF-kB inhibitor IkBalpha in bcl-xL transfectants confirmed the involvement of that inhibitor in bcl-xL-induced CXCL8 expression and promoter activity. In conclusion, our results demonstrate the role of NF-kB as the mediator of bcl-xL-induced CXCL8 up-regulation in glioblastoma cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18786178     DOI: 10.1111/j.1471-4159.2008.05661.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  16 in total

1.  Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells.

Authors:  D Trisciuoglio; C Gabellini; M Desideri; Y Ragazzoni; T De Luca; E Ziparo; D Del Bufalo
Journal:  Cell Death Differ       Date:  2011-01-14       Impact factor: 15.828

2.  Prognostic significance of kappaB-Ras1 expression in gliomas.

Authors:  Hong Lin; Yangang Wang; Xiang Zhang; Bolin Liu; Wei Zhang; Jinxiang Cheng
Journal:  Med Oncol       Date:  2011-02-08       Impact factor: 3.064

Review 3.  Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review).

Authors:  Roberto Gambari; Eleonora Brognara; Demetrios A Spandidos; Enrica Fabbri
Journal:  Int J Oncol       Date:  2016-05-04       Impact factor: 5.650

4.  Pharmacological Rac1 inhibitors with selective apoptotic activity in human acute leukemic cell lines.

Authors:  Natalia Fernández; Pablo Lorenzano Menna; Maia Cabrera; Emiliana Echeverria; Federico Remes Lenicov; Georgina Cardama; Nazareno Gonzalez; Carlos Davio
Journal:  Oncotarget       Date:  2017-10-04

5.  BCL-XL overexpression promotes tumor progression-associated properties.

Authors:  Daniela Trisciuoglio; Maria Grazia Tupone; Marianna Desideri; Marta Di Martile; Chiara Gabellini; Simonetta Buglioni; Matteo Pallocca; Gabriele Alessandrini; Simona D'Aguanno; Donatella Del Bufalo
Journal:  Cell Death Dis       Date:  2017-12-13       Impact factor: 8.469

Review 6.  The Role of Selected Chemokines and Their Receptors in the Development of Gliomas.

Authors:  Magdalena Groblewska; Ala Litman-Zawadzka; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

Review 7.  Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer.

Authors:  Simona D'Aguanno; Donatella Del Bufalo
Journal:  Cells       Date:  2020-05-21       Impact factor: 6.600

8.  Regulation of IL-8 gene expression in gliomas by microRNA miR-93.

Authors:  Enrica Fabbri; Eleonora Brognara; Giulia Montagner; Claudio Ghimenton; Albino Eccher; Cinzia Cantù; Susanna Khalil; Valentino Bezzerri; Lisa Provezza; Nicoletta Bianchi; Alessia Finotti; Monica Borgatti; Giuseppe Moretto; Marco Chilosi; Giulio Cabrini; Roberto Gambari
Journal:  BMC Cancer       Date:  2015-10-08       Impact factor: 4.430

9.  Protect and serve: Bcl-2 proteins as guardians and rulers of cancer cell survival.

Authors:  Frédérique Braun; Sophie de Carné Trécesson; Joséphine Bertin-Ciftci; Philippe Juin
Journal:  Cell Cycle       Date:  2013-08-13       Impact factor: 4.534

10.  Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma.

Authors:  Claudia Friesen; Inis Hormann; Mareike Roscher; Iduna Fichtner; Andreas Alt; Ralf Hilger; Klaus-Michael Debatin; Erich Miltner
Journal:  Cell Cycle       Date:  2014-03-12       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.